摘要
目的:探讨替诺福韦治疗慢性重型乙型肝炎的近期疗效和安全性。方法:将64例HBV DNA阳性的慢性重型乙型肝炎患者分为治疗组32例及对照组32例,治疗组应用替诺福韦治疗,对照组予以恩替卡韦治疗,连续治疗8周。比较治疗前后临床症状,定期检测肝功能、HBVM、HBV DNA等指标。结果:替诺福韦治疗组的临床好转率、ALT及TBil复常率、HBV DNA及HBeAg阴转率及抗-HBe阳转率均明显高于对照组(P<0.05)。结论:替诺福韦治疗慢性重型乙型肝炎有较好的抗病毒效果,可显著改善患者临床症状,提高生存率。
Objective：To evaluate the short-term therapeutic efficacy and safety of Tenofovir on patients with Severe Chronic Hepatitis B.Methods：64 patients with Severe Chronic Hepatitis B and positive HBV DNA were randomly divided into the control group and the therapeutic group.The therapeutic groups were treated with Tenofovir and the control groups were treated with Entecavir for 8 weeks.The clinical symptoms,liver functions,HBVM、HBV DNA were compared before and after treatment.Results：The clinical improvement rate,normalization rate of ALT and Tbil,negative conversion rate of serum HBV-DNA,HbeAg and positive conversion rate of Hbe-Ab were higher than the control group（P0.05）.Conclusion：Treatment with Tenofovir on patients with Severe Chronic Hepatitis B can enhance its antivirus actions,improve clinical symptoms and increase survival rate.
出处
《现代生物医学进展》
CAS
2012年第36期7089-7091,共3页
Progress in Modern Biomedicine
